MAY 23, 2019 11:29 PM PDT

Miracle Drug for Rare Genetic Disease Causes Price Concerns

WRITTEN BY: Nouran Amin

A newly approved “miracle drug” called Zolgensma will be used to treat children with spinal muscular atrophy, or SMA. Unfortunately, the therapeutic comes with a price target of $2.1 million for just a single dose to treat a child. However, Vas Narasimhan, the CEO of Novartis, the maker of Zolgensma, believes such a price is justifiable and thinks insurance companies should cover the cost.

“Critics are not actually thinking about how our healthcare systems work,” Vas Narasimhan said. “For transplants, we spend $3 million to $5 million [per patient] with far less efficacy than we see with medicine like this. We’re trying to price this at 50 percent of what is the current cost of care over ten years for these children.”

“I'm sure the company's going to try and push through laws to require insurers to pay for these drugs. The advocacy community that are often funded by the drug companies are going to push legislators to require insurers to pay for these drugs,” says Dr. Peter Bach, an epidemiologist and the director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York City.

According to the National Institute of Neurological Disorders and Stroke, babies diagnosed with SMA will later have weakened muscles as the disease progresses and eventually patients lose the ability to walk, talk, eat, and even breathe. SMA is a fatal genetic disease and affects approximately 1 in 11,000 babies with about 1 in every 50 Americans is a genetic carrier.

Learn more about Spinal Muscular Atrophy (SMA):

“In our early studies we’ve had 15 children who’ve been followed out to approximately four years and all the children are alive and doing well,” says Narasimhan. “The thing about SMA you have to remember is, children are developing mentally normally. So these are very bright children. They’ve lost the ability to move. So any regaining of function allows these children to start to experience life again. And I think that’s what we’re all here to do.”

Source: BioSpace

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 26, 2019
Drug Discovery
JUN 26, 2019
Drug Reverses Effects of Alcohol on the Brain
Recently, researchers have identified a drug that could help reverse the damaging effects of heavy alcohol consumption on the regeneration of neurons (brai...
JUN 26, 2019
Drug Discovery
JUN 26, 2019
New Drug Therapeutic for Portal Hypertension
According to a study published in the journal of the American Gastroenterological Association, drug therapy, called sivelestat, may effectively treat life-...
JUN 26, 2019
Drug Discovery
JUN 26, 2019
First Generic Naloxone Nasal Spray Approved To Treat Opioid Overdose
The U.S. Food and Drug Administration has approved the first generic naloxone hydrochloride nasal spray. The spray is called Narcan and is a life-saving me...
JUN 26, 2019
Microbiology
JUN 26, 2019
Disrupting tRNA in Bacteria - A Way to Fight Antibiotic Resistant Microbes
Antibiotic-resistant bacteria already cause the deaths of around 23,000 people every year, and that number is expected to rise dramatically....
JUN 26, 2019
Drug Discovery
JUN 26, 2019
Drug Treatment for Social Anxiety Proves Insufficient
In a Japanese study published in the journal Psychotherapy and Psychosomatics, antidepressant drugs targeted for treating patients with a social anxiety di...
JUN 26, 2019
Drug Discovery
JUN 26, 2019
Drug Regimen Improves Clinical Outcomes for Kidney Transplant Patients
Recent preliminary clinical trial results indicate the immunosuppressive drug belatacept can safely and effectively treat kidney transplant patients withou...
Loading Comments...